The liver cancer diagnostics market in North America is expected to grow from US$ 3,843.93 million in 2021 to US$ 6,666.24 million by 2028. It is estimated to grow at a CAGR of 8.2% from 2021 to 2028.
North America Liver Cancer Diagnostics Market The ability to accurately diagnose liver cancer progression is critical for selecting the appropriate treatment option. Further, various companies and organizations have taken enormous initiatives to develop and implement innovative solutions for the early identification of this disease in response to the rising demand. For instance, in March 2020, Roche Holding AG’s Elecsys GALAD score received the US Food and Drug Administration’s breakthrough device status for the early detection of an advanced form of liver cancer. North America Liver Cancer Diagnostics Market The Swiss drugmaker’s calculator combines factors including age, gender, and biomarker results to detect early-stage hepatocellular carcinoma, which is the most common form of liver cancer. Further, Elecsys GALAD score is designed to support clinicians by providing them with a timely and accurate diagnosis of hepatocellular carcinoma.
North America Liver Cancer Diagnostics Market
North America Liver Cancer Diagnostics Market Liver cancer, particularly hepatocellular carcinoma (HCC), is one of the leading causes of cancer-related mortality worldwide. The increasing prevalence of liver disease, particularly due to rising rates of chronic hepatitis B and C infections, alcohol-related liver disease, and non-alcoholic fatty liver disease (NAFLD), has led to an increase in the number of liver cancer cases. In North America, the growing demand for effective and early diagnostic tools to detect liver cancer has fostered the expansion of the liver cancer diagnostics market.This article will examine the factors driving the growth of the North American liver cancer diagnostics market, key diagnostic methods, market challenges, and future prospects in the region.
๐ ๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐จ๐ฉ๐ฒ@ https://www.businessmarketinsights.com/sample/BMIRE00025043
North America Liver Cancer Diagnostics Market The research and development (R&D) expenditure in 2021 was US$ 14.65 billion, and in 2020, it was US$ 13.17 billion. The research and development (R&D) expenditure grew by 14% on a core basis in F. Hoffmann-La Roche Ltd., North America Liver Cancer Diagnostics Market mostly driven by late-stage investments in oncology, ophthalmology, and personalized healthcare. In 2021, the R&D investment in the diagnostic division was US$ 1,878.92 million. Similarly, In November 2019, EXACT Sciences Corporation received the Food and Drug Administration’s (FDA) breakthrough designation for its blood-based test for early detection of liver cancer.Additionally, in June 2020, National Institutes of Health (NIH) scientists developed blood tests to help improve liver cancer screening, led by researchers at the National Cancer Institute (NCI). In addition, in June 2019, CancerSEEK, a liquid biopsy test, was designed by researchers at Johns Hopkins University. North America Liver Cancer Diagnostics Market The test was designed to diagnose multiple cancers, including stomach, liver, ovarian, and esophageal, at an early stage, facilitating early treatment. Therefore, the increasing R&D investments and development of diagnostic tests for the detection of liver cancer are driving the liver cancer diagnostics market.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America Liver cancer diagnostics market at a substantial CAGR during the forecast period.
๐๐ก๐ ๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ
Abbott
bioMerieux SA
F. HOFFMANN-LA ROCHE LTD.
Illumina, Inc.
Koninklijke Philips N.V.
QIAGEN
Siemens Healthineers AG
THERMO FISHER SCIENTIFIC INC.
GE Healthcare
Perspectum
๐๐ ๐ฎ๐ฅ๐ฅ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐ข๐ง๐ค @ https://www.businessmarketinsights.com/reports/north-america-liver-cancer-diagnostics-market
Drivers of Market Growth
Several factors are contributing to the expansion of the liver cancer diagnostics market in North America:
1.Rising Incidence of Liver Cancer: North America Liver Cancer Diagnostics Market The number of liver cancer cases in North America has been steadily increasing, driven by the growing incidence of risk factors like chronic hepatitis infections, alcohol abuse, and NAFLD. The Centers for Disease Control and Prevention (CDC) has reported a significant rise in the rates of liver cancer in the United States in recent years, underscoring the urgent need for improved diagnostic tools.
2.Technological Advancements in Diagnostic Tools: North America Liver Cancer Diagnostics Market The development of advanced imaging technologies such as contrast-enhanced ultrasound (CEUS), elastography, and molecular diagnostic tests has made early detection of liver cancer more accurate and accessible. The increasing adoption of non-invasive diagnostic technologies such as liquid biopsy and blood-based biomarker assays has also contributed to the marketโs growth.
3.Government Initiatives and Awareness Campaigns: North America Liver Cancer Diagnostics Market Governments and health organizations are investing in liver cancer awareness and screening programs, aiming to detect liver cancer in its early stages when treatment options are more effective. This has spurred the demand for liver cancer diagnostic services, driving market growth.
4.Improved Healthcare Infrastructure: North America Liver Cancer Diagnostics Market The availability of state-of-the-art healthcare facilities, especially in urban areas across the United States and Canada, has increased the accessibility of diagnostic tests. The growing number of specialized cancer centers is contributing to the rise in diagnostic procedures.
5.Aging Population: North America Liver Cancer Diagnostics Market North America has an aging population, and with age being one of the major risk factors for liver cancer, the incidence of liver cancer is expected to rise. This demographic trend is expected to drive the demand for liver cancer diagnostic services, as older individuals are more likely to develop liver disease and cancer.
Key Players and Competitive Landscape
The North American liver cancer diagnostics market is competitive, with a variety of players ranging from global pharmaceutical companies to specialized diagnostic firms. Key players include:
- Roche Holding AG: Roche is a leader in the liver cancer diagnostics market, particularly with the Elecsys GALAD score. Its strong R&D pipeline and strategic focus on oncology and personalized healthcare are key factors driving its success in the liver cancer diagnostics space. Roche’s ability to integrate biomarkers into diagnostics and its broad distribution network position it as a dominant player.
- EXACT Sciences Corporation: EXACT Sciences has made significant strides with its blood-based test for liver cancer. Its FDA breakthrough designation and focus on liquid biopsy make it a key player in the emerging field of non-invasive diagnostic solutions. With ongoing investment in R&D, the company is expected to continue expanding its presence in the market.
- Illumina: As a leader in genomic sequencing, Illumina is positioning itself to capitalize on the growing demand for personalized medicine in cancer diagnostics. Through advanced genetic testing and next-generation sequencing (NGS), Illuminaโs technologies are improving the detection of genetic mutations related to liver cancer, making them critical players in the diagnostic space.
- Abbott Laboratories: Abbott’s diagnostic portfolio, including its Alinity series and its work on biomarkers, offers cutting-edge solutions for liver cancer detection. Abbott is positioning itself well to leverage its expertise in immunoassays and diagnostics to develop more comprehensive tests for liver cancer, incorporating both biomarkers and imaging.
- Biomarker Startups and Innovators: Smaller players and startups are also emerging in the market, particularly in the realm of liquid biopsy and AI-based diagnostic tools. These companies are often more nimble and can quickly adapt to changing market conditions and patient needs. Collaborations and partnerships with larger organizations could help these startups scale and reach a broader audience.
Regional Nuances and Market Dynamics
The North American market is particularly dynamic due to varying healthcare infrastructure, economic conditions, and regulatory frameworks between the United States and Canada. Below are some regional nuances:
- United States:
- The U.S. healthcare system is highly advanced, offering ample opportunities for the adoption of sophisticated diagnostic tools. However, the fragmented nature of the healthcare system, with various private insurers and government programs (Medicare, Medicaid), can complicate market access and reimbursement for new diagnostics. Companies must navigate these complexities to ensure widespread adoption.
- The U.S. market also sees a higher burden of liver disease linked to alcohol consumption, obesity, and hepatitis. These factors contribute to a larger pool of potential liver cancer patients, thereby driving demand for diagnostics.
- Canada:
- Canadaโs public healthcare system provides a more centralized approach to healthcare delivery, which can facilitate the introduction of new diagnostic tools at the national level. However, the market is smaller than the U.S., which may limit opportunities for rapid growth.
- The Canadian market has a growing aging population, contributing to a higher prevalence of liver cancer. The relatively high levels of government-funded healthcare research and collaborations with academic institutions are key drivers of innovation in the Canadian diagnostic sector.
๐๐๐จ๐ฎ๐ญ ๐๐ฌ:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.
You can see this-
North America Liquid Biopsy Market- https://postyourarticle.com/north-america-liquid-biopsy-market-identifying-roles-and-objectives-in-coming-years-till-2027/
North America Healthcare Contract Research Organizations (CRO) Services Market- https://www.globalpostnews.com/uncategorized/north-america-healthcare-contract-research-organizations-cro-services-market-size-growth-status-analysis-and-forecast-2027/
North America Railway Cyber Security Market- https://www.openpr.com/news/3929498/north-america-coffee-beans-market-regional-share-global-size
North America Acetonitrile Market- https://businessmarketreportsblog.wordpress.com/2025/03/21/north-america-acetonitrile-market-size-growth-status-analysis-and-forecast-2027/
